Roche Holding stock gains as Goldman Sachs lifts target on cancer data

Published on 09/16/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock trades higher on September 16, 2026 after new lung cancer study data and a Goldman Sachs target increase to 366.00 CHF. Investors weigh the recent share move against interim revenue trends and the Swiss blue-chip’s SMI role.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH0012032048) was trading higher on the SIX Swiss Exchange at 362.10 CHF as of September 16, 2026, reflecting a 0.42% gain versus the prior close and renewed interest following fresh oncology study data and a higher analyst price target.

Analyst target raised and new cancer data

According to Finanzen.at on September 15, 2026, Goldman Sachs raised its price target for Roche from 349.00 CHF to 366.00 CHF while maintaining a Neutral rating, signaling modest upside potential but no outright conviction call from the US investment bank.

As BioPharma Dive reported on September 15, 2026, Roche presented Phase 3 data in lung cancer for its investigational antibody drug conjugate nicknamed tam-peli, showing the drug cut the risk of death by 54% versus chemotherapy and reduced disease progression risk by 71% in a Chinese study population.

In the same report, BioPharma Dive highlighted that patients treated with tam-peli achieved a median overall survival of 13.3 months, roughly four months longer than those on topotecan chemotherapy, and that the response rate was about 59% compared with around 10% under the chemo regimen.

Share performance and SMI context

Per data from Investing.com, Roche Holding participation shares closed at 362.10 CHF on September 16, 2026, after trading between an intraday high of 364.00 CHF and a low of 359.20 CHF on volume of 304,290 shares.

In intraday trading, the stock was cited as gaining 0.7% to 363.00 CHF in the early afternoon on September 16, 2026, placing Roche among the outperformers in the Swiss Market Index, which stood around 13,860 points at that time, as reported by finanzen.ch.

Earlier, on September 15, 2026, the participation share had closed lower at 358.70 CHF after touching an intraday low of 355.80 CHF, illustrating a swing of about 1.0% from that low to the subsequent closing level of 362.10 CHF, according to finanzen.ch.

Interim fundamentals and risk factors

While the latest oncology data support Roche Holding stock sentiment, investor focus also remains on interim revenue and earnings trends from the most recent quarterly and half-year figures, which frame how much upside innovative drugs like tam-peli can deliver to the broader business over time.

According to Roche, the company positions oncology as a key growth pillar alongside immunology and neuroscience, and pipeline advances in areas like lung cancer are intended to support medium-term revenue growth and margins.

However, as BioPharma Dive noted, Roche still needs to validate the Chinese study results in broader global trials, meaning regulatory timelines and reimbursement decisions remain key risk factors that could delay or moderate the commercial impact of tam-peli.

Closing share price and investor takeaway

Roche Holding stock closed at 362.10 CHF on the SIX Swiss Exchange on September 16, 2026, up 0.42% from the prior close, with the shares trading near the recent intraday high of 364.00 CHF as investors balance encouraging lung cancer trial data and a raised Goldman Sachs price target against the execution risks inherent in late-stage oncology development.